跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
COPD therapeutics
首页
药物
COPD therapeutics
COPD therapeutics
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTSMETHODS FOR
US 2011086019 A1
申请人: DOMANTIS LTD
优先权: 2008
US
6 件公开
RNAI AGENTS FOR INHIBITING EXPRESSION OF BETA-ENAC, COMPOSITIONS THEREOF, AND METHODS OF USE
EP 4051798 A4
申请人: ARROWHEAD PHARMACEUTICALS INC
优先权: 2019
EP
US
WO
4 件公开
Polypeptides, antibody variable domains and antagonists
US 8398979 B2
申请人: JESPERS LAURENT
优先权: 2008
CN
US
4 件公开
Composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom, as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof
US 9655871 B2
申请人: YUNGJIN PHARMACEUTICAL CO LTD
优先权: 2013
US
WO
4 件公开
INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
US 2009142806 A1
申请人: WYETH CORP
优先权: 2005
CN
US
3 件公开
Methods of diagnosing tumors using the G-protein coupled receptor (GPCR), RAI-3
US 7517652 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2003
US
3 件公开
Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
US 9982265 B2
申请人: UNIV TEXAS
优先权: 2015
US
RNAi AGENTS FOR DUAL INHIBITION OF EXPRESSION OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) AND INTERLEUKIN 33 (IL33), COMPOSITIONS THEREOF, AND METHODS OF USE
WO 2026096997 A1
申请人: ARROWHEAD PHARMACEUTICALS INC
优先权: 2024
WO
药物
反馈